RepliCel Retains Christina Cameron as Canadian Investor Relations Consultant

RepliCel Retains Christina Cameron as Canadian Investor Relations Consultant 
VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 06/05/14 --  
RepliCel Life Sciences Inc. (TSX VENTURE: RP)(OTCQB: REPCF), today
announced that it has retained Christina Cameron as its Canadian
Investor Relations consultant to create and execute the company's
investor relations strategy within Canada. 
Ms. Cameron is a life sciences capital markets expert with over 13
years of experience in investor relations and investment banking. Her
extensive network of sell-side, buy-side, retail investors and
industry partners will be invaluable to RepliCel as it looks to
broaden its Canadian stakeholder base. 
Prior to consulting, Ms. Cameron led the in-house investor relations
program for Medicago Inc., a TSX listed Canadian life science
company, which was recently acquired by Mitsubishi Tanabe Pharma
Corporation, a big pharma company. She has also spent 10 years in the
life science capital markets industry as a senior member of the TMX
Group's investor relations arm and as a healthcare banker at HSBC
Securities and Vengate Capital. 
"Ms. Cameron's experience will be a significant asset to the company
as we continue to develop our strategic investor relations program,"
stated Gemma Fetterley, VP Finance of RepliCel. 
Pursuant to its Stock Option Plan, the Company granted 100,000
options to Ms. Cameron. The options vest over a one year period and
are exercisable at $0.65 per share until June 1, 2019. 
About RepliCel Life Sciences 
RepliCel is a regenerative medicine company developing autologous
cell therapies that treat functional cellular deficits including
chronic tendon injuries, pattern baldness and damaged and aging skin.
Phase 2 trials are planned for RCT-A-01, a treatment for chronic
Achilles tendinosis and RCH-01, a treatment for pattern baldness in
2014. A Phase 1 trial for RCS-01, a treatment for damaged and aging
skin is also targeted for 2014. All products are based on RepliCel's
innovative technology which utilizes cells isolated from a patient's
own healthy hair follicles which are then replicated using the
company's proprietary manufacturing and cell expansion platform.
Shiseido Company has acquired an exclusive geographic license for
RCH-01 in certain Asian countries including Japan, China and South
On Behalf of the Board 
RepliCel Life Sciences Inc. 
David Hall, President and Chief Executive Officer 
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release. 
RepliCel Life Sciences
Tammey George
Director of Communications
US Investor Relations:
Westwicke Partners, LLC
Robert H. Uhl, Managing Director
Canadian Investor Relations:
Christina Cameron
Press spacebar to pause and continue. Press esc to stop.